Facebook tracking pixel
E04.1
ICD-10-CM
Thyroid Mass

Find comprehensive information on Thyroid Mass diagnosis, including clinical documentation, medical coding (ICD-10, SNOMED CT), differential diagnosis, ultrasound findings, and thyroid nodule evaluation. Learn about the latest guidelines for managing a thyroid mass, fine-needle aspiration biopsy procedures, and best practices for healthcare professionals. Explore resources for accurate thyroid nodule documentation and appropriate medical coding for optimal reimbursement. This resource addresses key aspects of thyroid mass diagnosis, supporting accurate and efficient clinical care.

Also known as

Thyroid Nodule
Thyroid Lesion

Diagnosis Snapshot

Key Facts
  • Definition : Abnormal growth or lump in the thyroid gland, can be benign or malignant.
  • Clinical Signs : Neck swelling, difficulty swallowing, voice changes, hoarseness, pain.
  • Common Settings : Primary care, endocrinology, otolaryngology (ENT).

Related ICD-10 Code Ranges

Complete code families applicable to AAPC E04.1 Coding
E05.0-E05.9

Thyroiditis and other thyroid disorders

Covers various thyroid disorders, including inflammatory conditions like thyroiditis.

D34

Benign neoplasm of thyroid gland

Specifies non-cancerous growths or tumors within the thyroid gland.

C73

Malignant neoplasm of thyroid gland

Identifies cancerous tumors originating in the thyroid gland.

R94.8

Abnormal findings on diagnostic imaging of thyroid

Encompasses unusual results from imaging studies focused on the thyroid, possibly indicating a mass.

Code-Specific Guidance

Decision Tree for

Follow this step-by-step guide to choose the correct ICD-10 code.

Is the thyroid mass specified as malignant?

Code Comparison

Related Codes Comparison

When to use each related code

Description
Thyroid Mass
Thyroid Nodule
Thyroid Cyst

Documentation Best Practices

Documentation Checklist
  • Thyroid mass size, location, and characteristics documented.
  • Symptoms: dysphagia, voice changes, pain, etc.
  • TSH, T3, T4 levels recorded.
  • FNA biopsy results if performed.
  • Imaging studies: ultrasound, CT, or MRI findings.

Coding and Audit Risks

Common Risks
  • Unspecified Laterality

    Coding lacks laterality (right, left, bilateral) when documented, impacting reimbursement and data accuracy. Relevant for medical coding, CDI, healthcare compliance.

  • Unconfirmed Diagnosis

    Coding a suspected thyroid mass as confirmed without definitive diagnosis (e.g., biopsy) violates coding guidelines. Impacts medical coding, CDI, and healthcare compliance.

  • Missing Solitary Nodule Detail

    Failure to distinguish single nodule from multinodular goiter affects severity coding and risk adjustment. Relevant for medical coding, CDI, healthcare compliance.

Mitigation Tips

Best Practices
  • Document nodule size, location, characteristics for accurate ICD-10 coding (e.g., C73).
  • Use standardized terminology for thyroid mass diagnoses: specify if benign, malignant, or indeterminate.
  • Ensure complete ultrasound reporting with TIRADS classification for proper CPT coding and CDI.
  • Regularly review pathology reports for discrepancies impacting diagnosis and medical coding accuracy.
  • Implement compliant FNA biopsy documentation protocols per CMS guidelines for risk adjustment.

Clinical Decision Support

Checklist
  • Confirm thyroid mass location, size via palpation & imaging (ICD-10 L76, CPT 76536)
  • Evaluate thyroid function: TSH, T3, T4 levels (ICD-10 E03.9, CPT 84443)
  • Assess for lymphadenopathy: document size, location (ICD-10 I88.9, CPT 76882)
  • Review patient history: dysphagia, voice changes (ICD-10 R13.1, R49.0)

Reimbursement and Quality Metrics

Impact Summary
  • Thyroid Mass reimbursement hinges on accurate coding (ICD-10 E04-E07) and documentation of size, location, and related symptoms for optimal payer outcomes.
  • Quality metrics for Thyroid Mass include timely biopsy, ultrasound, and FNA result reporting impacting hospital quality scores and potential penalties.
  • Proper coding, including laterality (ICD-10 modifiers), is crucial for accurate thyroid mass diagnosis reimbursement, avoiding denials and maximizing revenue.
  • Thyroid nodule evaluation and management guideline adherence significantly influence hospital quality reporting metrics and overall patient outcomes.

Streamline Your Medical Coding

Let S10.AI help you select the most accurate ICD-10 codes. Our AI-powered assistant ensures compliance and reduces coding errors.

Frequently Asked Questions

Common Questions and Answers

Q: What is the recommended initial workup for a newly discovered thyroid nodule in a patient with no concerning symptoms, including appropriate next steps based on Bethesda classification?

A: The initial workup for a newly discovered, asymptomatic thyroid nodule should begin with a thorough history and physical examination, focusing on risk factors for thyroid cancer such as family history, radiation exposure, and rapid nodule growth. Serum TSH levels should be measured. Thyroid ultrasound is the cornerstone of nodule evaluation, assessing size, composition, and features suggestive of malignancy. Fine-needle aspiration (FNA) biopsy is guided by ultrasound findings and the Bethesda System for Reporting Thyroid Cytopathology. Bethesda category II (benign) typically warrants observation with repeat ultrasound in 6-12 months. Bethesda III (atypia of undetermined significance/follicular lesion of undetermined significance) often requires repeat FNA or molecular testing. Bethesda IV (follicular neoplasm/suspicious for a follicular neoplasm) generally necessitates surgical excision or lobectomy. Bethesda V (suspicious for malignancy) and VI (malignant) typically lead to surgical resection, usually total thyroidectomy. Explore how S10.AI can integrate Bethesda classification guidelines into your diagnostic workflow for streamlined decision-making.

Q: How can I differentiate benign thyroid nodules from malignant ones based on ultrasound features, and when is calcitonin testing indicated for thyroid nodule evaluation?

A: Differentiating benign from malignant thyroid nodules on ultrasound relies on evaluating several key features. Benign features include a completely cystic composition, an entirely spongiform nodule, or a dominant cystic nodule with a thin septation without solid components. Suspicious sonographic features suggestive of malignancy include hypoechogenicity, microcalcifications, irregular margins, taller-than-wide shape, and increased vascularity. While no single feature is definitively diagnostic, the combination of these findings helps stratify risk. Calcitonin testing is typically indicated in patients with a strong family history of medullary thyroid cancer (MTC), a palpable nodule with suspicious ultrasound features concerning for MTC, or in the presence of symptoms suggestive of MTC such as diarrhea or flushing. Consider implementing a standardized ultrasound reporting system to ensure consistent and accurate thyroid nodule assessment. Learn more about how S10.AI can enhance your diagnostic accuracy by incorporating ultrasound characteristics and calcitonin results into a comprehensive risk assessment model.

Quick Tips

Practical Coding Tips
  • Code thyroid nodule size precisely
  • Document FNA results with Bethesda category
  • Specify solitary or multinodular
  • If malignant, code laterality and size
  • Distinguish benign vs. suspicious features

Documentation Templates

Patient presents with concerns regarding a thyroid mass, nodule, or goiter.  Chief complaint includes (document specific patient complaint, e.g., neck swelling, dysphagia, dyspnea, voice changes, or asymptomatic incidental finding).  Review of systems includes (document pertinent positives and negatives related to thyroid function, such as changes in weight, energy levels, bowel habits, temperature sensitivity, palpitations, and menstrual cycles).  Past medical history, family history, and social history were reviewed and are relevant for (document relevant medical history, including family history of thyroid cancer, multiple endocrine neoplasia, radiation exposure, and smoking history).  Physical examination reveals (describe the size, shape, consistency, mobility, and tenderness of the thyroid gland, as well as the presence or absence of cervical lymphadenopathy).  Differential diagnosis includes thyroid adenoma, thyroid cyst, thyroid carcinoma, Hashimoto's thyroiditis, Graves' disease, and multinodular goiter.  Preliminary diagnostic workup includes thyroid ultrasound to assess the nodule characteristics (size, composition, echogenicity, margins, calcifications, and vascularity) and thyroid function tests (TSH, free T4, and free T3) to evaluate thyroid hormone levels.  Further evaluation may include fine-needle aspiration biopsy (FNAB) for cytological analysis if indicated based on ultrasound findings and risk stratification using Thyroid Imaging Reporting and Data System (TI-RADS) classification.  Management plan includes (discuss treatment options based on diagnosis, including watchful waiting, medical management with thyroid hormone suppression therapy, radioactive iodine therapy, or surgical intervention such as thyroidectomy).  Patient education provided regarding the nature of thyroid nodules, potential complications, and the importance of follow-up care.  Referral to endocrinology may be considered for further evaluation and management.  ICD-10 codes and CPT codes will be assigned based on the final diagnosis and procedures performed.
Thyroid Mass - AI-Powered ICD-10 Documentation